
Judge increases the amount of damages Gilead owes Bristol-Myers Squibb in CAR-T legal dispute
pharmafile | April 14, 2020 | News story | Manufacturing and Production | Bristol-Myers Squibb, Gilead, bristol myers squibb
A judge has ruled that Gilead Sciences owe Bristol-Myers Squibb (BMS) additional funds after infringing on one of the company’s patents.
In December, a California jury decided to award Bristol-Myers Squibb $752 million regarding Gilead’s CAR-T treatment Yescarta. Gilead had acquired Kite Pharma in 2017 to gain Yescarta, and Bristol-Myers Squibb alleged the treatment’s development was based on a patent owned by Juno therapeutics, that BMS acquired in 2018.
As a result of the new ruling, US District Judge Philip S. Gutierrez boosted the amount Gilead owes BMS from $752 million to $1.2 billion. This additional cost is labelled as “enhanced damages.”
Gilead plans to appeal the verdict and told the Times it believes that the ruling is legally “unsupportable” and the company believes it will be reversed. They maintain that Kite developed Yescarta independently and did not infringe on the Juno’s patent.
Yescarta was first approved by the FDA in 2017, and was the first CAR-T treatment for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Conor Kavanagh
Related Content

Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …

Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …

Bristol Myers Squibb reports positive results for psoriatic arthritis treatment
Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, …






